BC, CNM, RNFA, spoke about the oncology nurse’s and APP’s roles in managing chemotherapy-induced peripheral neuropathy in ...

Chemotherapy-induced peripheral neuropathy (CIPN) is a common and often debilitating side effect of cancer treatment, particularly associated with certain chemotherapeutic agents like taxanes and ...

Four in every 10 cancer patients treated with chemotherapy develop severe peripheral nerve pain, a new evidence review ...

Four in every 10 cancer patients treated with chemotherapy develop severe peripheral nerve pain, a new review suggests.

Worldwide, cancer chemotherapy is linked to persistent severe peripheral nerve pain (neuropathy) for around four in every 10 ...

Subgroup analyses showed that patients treated with platinum-based agents and taxanes had the highest prevalence of chronic ...

An APP’s research is focused on chemo-induced peripheral neuropathy in Black breast cancer survivors and its impact on their long-term quality of life. Given the significant number of breast cancer ...

Chemotherapy has been known to cause damage to peripheral nerves, and sometimes the pain is chronic and severe enough that chemotherapy doses are reduced or discontinued. But prior research has not ...

“Peripheral neuropathy is a degenerative disease, meaning it just keeps getting worse over time. We often associate it with diabetes, but there’s also chemotherapy-induced peripheral ...